Boston, MA, USA and London, UK – 8 April...
News
ISOQOL 30th Annual Conference take-aways
The International Society for Quality of Life...
ISPOR EU 2023
ISPOR Europe is on the horizon and we’ll be...
30 Years of ISOQOL: Quality of Life – making it relevant
The 30th annual ISOQOL conference is taking...
MyRealWorld MG study announcement
The MyRealWorld MG study, a longitudinal digital...
American Health Research study launch
We are delighted to announce that this month,...
Join our ISPOR short course
Join Dr Mark Larkin, Dr Catherine Bottomley, and...
ISPOR Europe 2022
This year’s conference theme is “Collaborating...
ISOQOL Annual Conference 2022 – attend our workshop
The 29th annual ISOQOL conference is taking place in Prague, October 19–22. This year, the theme will be “Redefining boundaries – breaking new ground in patient-centered outcomes research”. We’ll be there, will you?
We will be hosting a workshop on “Balancing measurement science with user experience practices in eCOA migration” on the first day of the conference at 9am local time.
MyRealWorld™ MG reaches over 2,000 participants!
As of late April, the MyRealWorld™ MG (MRW MG)...
It’s ISPOR 2022 – let’s talk!
During ISPOR 2022, speak to the Vitaccess team...
MyRealWorld™ MG: Study launch in Denmark
The MyRealWorld™ MG (MRW MG) study about the impact of myasthenia gravis on patients’ lives has added Denmark to its list of study countries. This means that the digital real-world evidence study, which has been ongoing since December 2019, now operates across nine countries: the US, Canada, Japan, Germany, the UK, France, Italy, Spain, and most recently, Denmark.
Envision Pharma Group and Vitaccess create a global partnership
Envision Pharma Group and Vitaccess create a...
Vitaccess at Virtual ISPOR Europe 2021
ISPOR Europe 2021 is just around the corner and the Vitaccess team is looking forward to sharing insights with you during the event as well as our poster presentations.
Early access innovator, RareiTi, and innovative research organization, Vitaccess, partner on real-world data services in rare disease
RareiTi Inc., a data-driven early access and clinical patient services company, and Vitaccess Ltd, a multi-award-winning digital real-world evidence (RWE) research and strategy specialist, announce a collaboration offering unique services in RWE to support biopharmaceutical companies in rare disease.
Vitaccess receives ISO 9001 and ISO 27001 certifications
Adverse events (AEs), particularly with drug therapies, remain a challenge in modern healthcare. The increasing complexity of cancer therapeutics, an ageing population, and rising multimorbidity all continue to contribute to and complicate safety issues for patients. However, while our understanding of AEs should be evolving, and our AE storytelling for patients should be more engaging, reporting of AEs really has not changed. Indeed, AE narratives remain directed at clinicians and regulators, rather than to patients. We believe there is value in being able to tell patients an AE narrative.
Vitaccess rebrand celebrates 4 years of ‘real progress’
Adverse events (AEs), particularly with drug therapies, remain a challenge in modern healthcare. The increasing complexity of cancer therapeutics, an ageing population, and rising multimorbidity all continue to contribute to and complicate safety issues for patients. However, while our understanding of AEs should be evolving, and our AE storytelling for patients should be more engaging, reporting of AEs really has not changed. Indeed, AE narratives remain directed at clinicians and regulators, rather than to patients. We believe there is value in being able to tell patients an AE narrative.
Vitaccess wins a Queen’s Award for Enterprise
Adverse events (AEs), particularly with drug therapies, remain a challenge in modern healthcare. The increasing complexity of cancer therapeutics, an ageing population, and rising multimorbidity all continue to contribute to and complicate safety issues for patients. However, while our understanding of AEs should be evolving, and our AE storytelling for patients should be more engaging, reporting of AEs really has not changed. Indeed, AE narratives remain directed at clinicians and regulators, rather than to patients. We believe there is value in being able to tell patients an AE narrative.
Vitaccess, one of the 50 Game Changers 2021
ConnectTVT, the platform joining the tech and digital dots in the Thames Valley, has announced the brand new Game Changers 2021 cohort. The programme brings together the Thames Valley’s breakthrough tech and digital startups and scaleups, making global impact in their industries through market-changing technologies, innovation and world-class talent.
Tech Nation announces upscale 6.0 cohort
Vitaccess will join 32 other businesses described by Tech Nation as “the UK’s best-performing tech companies” on a six-month program aimed at supercharging growth. The program offers the chance to work with an exciting group of leaders and to tackle the new challenges that founders are facing around remote working, fundraising and culture.
Vitaccess awarded Innovate UK loan
Digital healthcare scale-up Vitaccess announces award of prestigious Innovate UK loan.
Vitaccess, a full-service digital research provider delivering real-time patient-reported data, has been successful in its application for an Innovate UK loan. The funding is provided through loan competitions to UK-based small or medium-sized enterprises (SMEs) by Innovate UK, part of UK Research and Innovation, and the Government’s modern industrial strategy.
Vitaccess donates £10,000 to Melanoma UK
Award-winning digital health company Vitaccess is delighted to announce that, as part of their syndicated project with patient support charity Melanoma UK, they are donating £10,000 towards an Adamo Horus HS800 mole mapper for the Royal Liverpool and Broadgreen University Hospitals NHS Trust.




















